2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150Cardiogen is a short tetrapeptide (H-Ala-Glu-Asp-Arg-OH, also abbreviated as ADER) derived from cardiac tissue and belongs to a class of peptides developed to support organ-specific regulation.
Studied initially in Eastern Europe, Cardiogen is designed to interact with cardiomyocytes and the cardiac conduction system, where it may influence gene expression linked to cell survival, protein synthesis, and myocardial repair [1].
Its peptide sequence allows it to function as a signaling molecule, potentially modulating various cellular pathways involved in cardiac metabolism and structural integrity.
As there is no clinical study on the Cardiogen peptide to date, it remains a research compound without approved therapeutic use. Cardiogen remains under investigation for its potential role in supporting heart cell homeostasis.
Cardiogen may support cardiomyocyte survival by maintaining structural and functional stability in cells exposed to stress.
Although the precise molecular mechanisms remain under investigation, experimental reports suggest that Cardiogen may modulate pathways involved in apoptosis [2].
Rather than acting as a direct inhibitor, Cardiogen could influence cellular homeostasis, potentially helping reduce premature loss of cardiac cells.
In a rat model of myocardial infarction (MI), administration of Cardiogen resulted in a three-fold reduction in mortality, reduced necrotic heart tissue, and preserved glycogen reserves [3].
These findings suggest that Cardiogen preserves and protects cardiac tissue by stabilizing mitochondrial integrity and modulating apoptosis.
Cardiogen has been studied for its potential to stimulate cardiomyocyte proliferation and enhance reparative biosynthesis, including the upregulation of anti-apoptotic factors necessary for tissue recovery.
An animal study extracted myocardial tissue explants from young (three-month-old) and aged (24-month-old) rats to evaluate the effect of Cardiogen and other amino acids on cell proliferation and apoptosis regulation [4].
After tissue exposure to 20 individual amino acids or to the synthetic tetrapeptide Cardiogen, all substances were tested at a concentration of 10⁻¹² M.
Among the 20 amino acids tested, 7 stimulated cell proliferation in young rats, while only 2 amino acids had any proliferative effect in aged rats.
However, Cardiogen demonstrated the strongest effect by:
This study demonstrates that Cardiogen exhibits pro-proliferative and anti-apoptotic effects in myocardial tissue from both young and aged rats at extremely low concentrations.
One mechanism proposed for Cardiogen is its modulation of extracellular matrix (ECM) remodeling. Following cardiac injury, excessive deposition of collagen and matrix proteins can lead to fibrosis, reducing myocardial elasticity and impairing contractile function [5]. If Cardiogen can help regulate fibroblast activity by balancing collagen synthesis and degradation, this may help preserve normal heart function after cardiac injury.
Beyond its relevance to cardiology research, Cardiogen has also been evaluated in experimental oncology for its potential effects on cell differentiation and gene regulation.
A preclinical in vivo study evaluated the effect of Cardiogen peptide on tumor growth in 78 aged rats implanted with M-1 sarcoma, a fast-growing connective tissue tumor [2].
Rats were divided into five total groups:
Results showed:
Cardiogen may help restore regulatory signals in dysplastic or malignant cells, potentially promoting a shift toward more normalized cellular behavior.
Further research is needed to clarify the molecular mechanisms behind these observations.
Cardiogen’s structure suggests that it may help maintain metabolic stability in cardiac cells, particularly under conditions of stress or aging.
Pro-proliferative effects may occur via DNA and RNA synthesis, a process essential for sustaining protein turnover and cellular maintenance.
This activity may indirectly support mitochondrial function by promoting the renewal of metabolic enzymes and structural proteins required for cardiac energy metabolism.
Although direct effects on ATP production have not been formally established, Cardiogen may contribute to overall energetic resilience in cardiomyocytes.
Further research is needed to clarify whether Cardiogen directly influences mitochondrial activity, oxidative phosphorylation, or glycogen storage.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Cardiogen is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
The paper proposes that the previously reported cardioprotective activity of Cardiogen is determined by its capacity to activate synthesis of cytoskeletal and nuclear matrix proteins. In cultured cells, this protein synthesis activation is said to stimulate cell proliferation and reduce apoptosis.
In a laboratory study using cultured mouse embryonic fibroblasts, Cardiogen, also called H-Ala-Glu-Asp-Arg-OH, was reported to enhance the expression of the nuclear matrix proteins lamin A and lamin C. The same study reported that the increase was by 2-3 times for lamin A and lamin C, alongside enhanced expression of cytoskeletal proteins actin, tubulin and vimentin.
In the in vitro study, Cardiogen (H-Ala-Glu-Asp-Arg-OH) was tested on cultured mouse embryonic fibroblasts. In these cultured cells, it was reported to enhance the expression of cytoskeletal proteins (actin, tubulin, vimentin) and nuclear matrix proteins (lamin A, lamin C).
Cardiogen is the name for the tetrapeptide H-Ala-Glu-Asp-Arg-OH, and this is its peptide sequence. A paper describes this tetrapeptide as having previously reported cardioprotective activity. In vitro, the paper proposes that this activity depends on the peptide's capacity to activate synthesis of cytoskeletal and nuclear matrix proteins, which stimulates cell proliferation and reduces apoptosis.
Cardiogen, also called H-Ala-Glu-Asp-Arg-OH, was studied in cultured mouse embryonic fibroblasts. In these cells, it enhanced the expression of the cytoskeletal proteins actin, tubulin and vimentin by 2-5 times. In the same study, the nuclear matrix proteins lamin A and lamin C were enhanced by 2-3 times.
In in vitro work, the paper proposes that the previously reported cardioprotective activity of Cardiogen is determined by its capacity to activate synthesis of cytoskeletal and nuclear matrix proteins. The paper states that this activation stimulates cell proliferation and reduces apoptosis, and these effects are presented as part of that proposed explanation. Based on the available facts, Cardiogen's effects on apoptosis and cell proliferation are proposed in cell studies, not reported as demonstrated results.
The paper states that cardioprotective activity has been previously reported for Cardiogen (H-Ala-Glu-Asp-Arg-OH). The paper proposes that this activity is determined by Cardiogen's capacity to activate synthesis of cytoskeletal and nuclear matrix proteins. According to the paper, this capacity stimulates cell proliferation and reduces apoptosis, a proposal made in in vitro study.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.